2024年10月2日 · Here we develop in vitro and in vivo high-throughput CRISPR–Cas9 screening platforms to systematically uncover gene knockouts that boost NSC activation in old mice. Our genome-wide screens in...

2023年1月16日 · Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases by...

2024年2月29日 · The archetypical Cas9 protein originating from Streptococcus pyogenes (SpCas9), the first Cas nuclease to be repurposed for genome editing, remains the most widely used gene editor due to its intrinsically high activity and specificity. 12,18 Cas9 forms an active nuclease in association with either crRNA-tracrRNA complexes or sgRNA guides. 11 ...

Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology causing a major upheaval in biomedical research. It makes it possible to correct errors in the genome and turn on or off genes in cells and organisms quickly, cheaply and with relative ease.

Thermostable clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas9) enzymes could improve genome-editing efficiency and delivery due to extended protein lifetimes.

2014年6月5日 · Here, we review the development and applications of the CRISPR-associated endonuclease Cas9 as a platform technology for achieving targeted perturbation of endogenous genomic elements and also discuss challenges and future avenues for innovation.

2020年10月23日 · Thus, the combination of SpyCas9 and AcrIIA4-Cdt1 is a cell cycle-dependent Cas9 activation system for accurate and efficient genome editing. The CRISPR-Cas9 system was originally...

2022年12月1日 · Therapeutic application of CRISPR/Cas9-engineered mesenchymal stem cell (MSCs) derived exosomes. Considering that the therapeutic potential of MSCs increases after engineering with CRISPR/Cas9, also their exosomes have a higher therapeutic potential than exosomes produced from intact MSCs.

2018年1月1日 · There are several methods available to deliver CRISPR/Cas9 and its components to the target cells. It includes viral, non-viral and physical methods to deliver plasmid or ribonucleoprotein (RNP) of CRISPR components.

There are several methods available to deliver CRISPR/Cas9 and its components to the target cells. It includes viral, non-viral and physical methods to deliver plasmid or ribonucleoprotein (RNP) of CRISPR components.